Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HCV Franchise by Year
Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M) ($M)
Gilead Sciences Total HCV Franchise: $386M in FY2023, down 1.5% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 386 | -1.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 392 | -11.3% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 442 | -21.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 562 | -22.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 729 | -5.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 767 | – | Form 10-K (filed 2021-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total HCV Franchise ($M), annual FY2018–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hcv-total-row
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.